Medincell Stock Rebounds Nearly 3% and Climbs to the Top of the SBF 120
The biotech company from Montpellier advances in the morning, erasing some of its weekly decline. The stock climbs to the top of the SBF 120, moving against a barely positive Parisian market. The rebound occurs in a calmed market environment, with a significant drop in the VIX.
A Rebound that Propels Medincell Among the Top Gainers of the SBF 120
Medincell's stock gains 2.71% to €25.78 during the session, positioning it among the top gainers of the SBF 120, while the broader index only advances by 0.28%. This movement mitigates the decline over the past seven days (-4.09%) and bolsters the monthly gain, now close to 7%. Over a year, the performance remains strong, at +61%.
The overall context is supportive for risk assets: the VIX falls by 7% to 17.44, indicating a relaxation in American volatility, while the CAC 40 slightly gains 0.31%. The biotech had experienced several sessions of decline since mid-July, with a drop of 2.5% in the last brief on July 15, making today's rebound even more noticeable in the ranking of the broader index.
Stock Still Below Its Three Moving Averages Despite Today's Rebound
The rebound is not enough to bring the stock above its technical benchmarks. At €25.78, the stock still trades below its MM20 (€27.15), MM50 (€27.02), and MM200 (€26.59), with a gap of around 5% on the shorter averages. The RSI at 39 indicates a still sluggish momentum, without a marked oversold configuration. The support at €24.08 has not been breached during the recent weeks' decline, and the stock remains distant from the €29.56 resistance which had already halted the rise in early July.
On the fundamentals side, the company had highlighted during the annual results publication on June 16, 2026, the commercial launch of Olanzapine LAI planned for Q4 2026 as a growth driver, while anticipating an increase in operating expenses to support the expansion. Based on the expected earnings per share, the stock is priced at about 56.3 times the earnings for the following fiscal year according to the consensus of analysts surveyed. Crossing the MM20 at €27.15 remains the next technical benchmark to validate an exit from the decline zone.
